Procter & Gamble (P&G) has agreed to acquire Thorne for $3.8 billion in cash, expanding its presence in the growing market for nutritional supplements and personalized wellness. The P&G acquisition of Thorne brings one of the best-known science-backed supplement brands into Procter & Gamble’s health and wellness portfolio.
Thorne will be acquired from L Catterton’s Flagship Fund, which took the company private in 2023. The transaction is expected to close later in 2026, subject to customary closing conditions and regulatory approvals.
With consumers’ increasing focus on self-care, prevention and wellness, the P&G acquisition of Thorne marks a major step in the company’s strategy to strengthen its Personal Health Care business.
P&G Acquisition of Thorne Expands Its Health Portfolio
The P&G Thorne acquisition gives P&G a premium wellness brand with a strong focus on science, product quality and relationships with healthcare practitioners.
Thorne has built its business around developing nutritional supplements using clinical research and an in-house team of doctors, researchers and scientists. Its products serve consumers, athletes and healthcare professionals, while its technology offerings include Taia, an AI-powered wellness advisor.
According to Thorne, it is trusted by tens of thousands of healthcare professionals, more than 100 professional sports teams and over seven million consumers.
P&G already has several health and supplement brands, including Metamucil, Align Probiotic and New Chapter. Adding Thorne gives the company another platform in the premium supplement segment while broadening its exposure to personalized health and wellness.
Paul Gama, CEO of P&G Health Care, said in a statement, “Together, we see an opportunity to bring Thorne’s science-backed wellness solutions to more consumers while continuing to build on the quality, credibility and innovation that have made the brand successful.”
P&G Acquisition of Thorne Follows Rapid Company Growth
The P&G Thorne deal also highlights the rapid increase in Thorne’s value under L Catterton.
L Catterton acquired Thorne for $680 million in 2023, after the company had gone public in 2021. According to reports, Thorne was forecasting annual sales of about $290 million in 2023 before the transaction, while the sales were expected to reach approximately $650 million in 2026.
For L Catterton, the P&G acquisition of Thorne is an opportunity to get back more than $3 billion on its 2023 investment.
P&G Thorne Deal Reflects Wider Supplement Market Shift
P&G’s Thorne purchase comes as major consumer companies compete for a stronger position in the vitamins, minerals and supplements market.
P&G acquisition of Thorne follows Unilever’s move to acquire US-based nutritional supplement brand Grüns. Another giant, Nestlé, is conducting a strategic review of its vitamins, minerals and supplements brands. This trend shows how established consumer companies increasingly see wellness and nutritional supplements as important growth categories.
The P&G Thorne acquisition therefore is not only an expansion of P&G’s healthcare portfolio but also another major transaction in an increasingly competitive consumer health market.
Future Steps in the P&G Thorne Acquisition
The P&G Acquisition of Thorne has not yet closed. The transaction remains subject to customary closing conditions and regulatory approvals, with completion expected later in 2026.
Thorne CEO Colin Watts said the company believes P&G is the right partner to help expand its impact while maintaining the standards of “science, quality, innovation, and trust” that have defined the brand.
For P&G, the transaction strengthens its position in premium wellness. For Thorne, the deal provides the backing of a global consumer company as it seeks to expand its pipeline.
